P528: Feasibility, satisfaction and machine learning analysis of factors influencing IBD patients’ trust in the mobile application Care4today IBDECCO'22Year: 2022
Authors: Costantino, A.(1,2);Vecchi, M.(1,2);Stocco, D.(3);Noviello, D.(4);Conforti, F.S.(1);Maregatti, M.(4);Caprioli, F.(1,2);
(1)IRCCS Ca’ Granda Ospedale Maggiore Policlinico Foundation, Gastroenterology and Endoscopy Unit, Milan, Italy;(2)University of Milan, Department of Pathophysiology and Transplantation, Milan, Italy;(3)Politecnico di Milano, Department of Mathematics, Milan, Italy;(4)University of Milan, Gastroenterology, Milan, Italy;
P529: Evolution of COVID19 serology in a real-life population of IMID patients. Results of the BELCOMID study: BELgian Cohort study of COVID-19 in Immune Mediated Inflammatory Diseases (IMID).ECCO'22Year: 2022
Authors: Geldof, J.(1);Sabino, J.(2);Ferrante, M.(2);Lambert, J.(3);Lapeere, H.(3);Hillary, T.(4);Van Laethem, A.(4);De Vlam, K.(5);Verschueren, P.(5);Lobaton, T.(1);Vermeire, S.(2);
(1)University Hospital Ghent, Department of Gastroenterology and Hepatology, Ghent, Belgium;(2)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(3)University Hospital Ghent, Department of Dermatology, Ghent, Belgium;(4)University Hospitals Leuven, Department of Dermatology, Leuven, Belgium;(5)University Hospitals Leuven, Department of Rheumatology, Leuven, Belgium;Studygroup: BELCOMID - BELCOMID studygroup received research grants from following pharmaceutical companies: Almirall Roche Janssen Pfizer Eli Lilly Amgen Biogen Mylan Leo Pharma.
P530: Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn’s disease - a systematic review with meta-analysisECCO'22Year: 2022
Authors: Attauabi, M.(1,2,3);Madsen, G.R.(1,2);Bendtsen, F.(1,2);Seidelin, J.B.(3);Burisch, J.(2);
(1)Copenhagen University Hospital- Hvidovre, Gastrounit- Medical Section, Hvidovre, Denmark;(2)University of Copenhagen- Hvidovre Hospital, Copenhagen Center for Inflammatory Bowel Disease in Children- Adolescents and Adults, Hvidovre, Denmark;(3)Herlev Hospital- University of Copenhagen, Department of Gastroenterology and Hepatology, Herlev, Denmark;
P531: Stringent screening strategy significantly reduces reactivation rate of Tuberculosis in Patients with Inflammatory Bowel Disease on anti-TNF therapy in a TB endemic regionECCO'22Year: 2022
Authors: Kumar, P.(1);Vuyyuru, S.K.(1);Kante, B.(1);Sahu, P.(1);Goyal, S.(1);Madhu, D.(1);Jain, S.(1);Ranjan, M.K.(1);Mundhra, S.(1);Golla, R.(1);Singh, M.(1);Virmani, S.(1);Gupta, A.(1);Yadav, N.(1);Kalaivani, M.(1);Sharma , R.(1);Das, P.(1);Makharia, G.(1);Kedia, S.(1);Ahuja, V.(1);
(1)All India Institute of Medical Sciences, Department of Gastroenterology and Human Nutrition, New Delhi, India;
P532: Proactive therapeutic drug monitoring improves clinical outcomes in patients with inadequate post-induction infliximab trough levelsECCO'22Year: 2022
Authors: Botto, I.(1);Coelho Rodrigues, I.(1);Serrazina, J.(1);Fernandes, S.(1);Bernardo, S.(1);Gonçalves, A.R.(1);Moura Santos, P.(1);Valente, A.(1);Correia, L.(1);Tato Marinho, R.(1);
(1)Centro Hospitalar Universitário Lisboa Norte, Serviço de Gastrenterologia, Lisbon, Portugal;
P533: Predictors of sustained remission after infliximab de-escalation in patients with inflammatory bowel diseasesECCO'22Year: 2022
Authors: Kantasiripitak, W.(1);Outtier, A.(2,3);Thomas, D.(1);Sabino, J.(2,3);Vermeire, S.(2,3);Ferrante, M.(2,3);Dreesen, E.(1);
(1)University of Leuven, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium;(2)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(3)University of Leuven, Department of Chronic Diseases and Metabolism, Leuven, Belgium;
P534: Effectiveness and safety of Adalimumab switch from originator to biosimilar in patients with inflammatory bowel disease in clinical remissionECCO'22Year: 2022
Authors: Gros , B.(1);Soto Escribano , P.(1);Marín Pedrosa , S.(1);Medina Medina , R.(2);Benítez , J.M.(1);Iglesias-Flores , E.(1);
(1)Reina Sofía University Hospital, Department of Gastroenterology, Córdoba, Spain;(2)Maimónides Biomedical Research Institute IMIBIC, Gastroenterology, Córdoba, Spain;
P535: Association of anti-Infliximab antibodies and HLADQA1*05 variant in ulcerative colitis : a retrospective single centre studyECCO'22Year: 2022
Authors: Aleman Gonzalez, H.(1);Sankaranarayanan, R.(1);Pattinson, A.(1);Turnbull, J.(1);Katie, S.(1);Whitehead, E.(1);Talbot, A.(1);Myers, S.(1);Sebastian, S.(1);
(1)Hull University Teaching Hospitals, Inflammatory Bowel Disease, Kingston Upon Hull, United Kingdom;
P536: Comparison of outcomes of infliximab biosimilar CT-P13 with infliximab originator in patients with inflammatory bowel diseaseECCO'22Year: 2022
Authors: Yüksel, I.(1,2);Baspınar, B.(1);Durak, M.B.(1);Kilic, V.(1);Kivrakoglu, F.(1,2);Guven, I.E.(1);Kosar, K.(1);Erdogan, C.(1);Alkan, A.(3);
(1)Ankara City Hospital, Gastroenterology, Ankara, Turkey;(2)Ankara Yildirim Beyazit University School of Medicine, Gastroenterology, Ankara, Turkey;(3)Ankara Yildirim Beyazit University School of Medicine, Biostatistics and Medical Informatics, Ankara, Turkey;
P537: Steroid use in patients with immune checkpoint inhibitor colitisECCO'22Year: 2022
Authors: Crothers-Stomps, L.(1);Mohsen, W.(1);Kakkadasam Ramaswamy, P.(1);Mason, R.(2);Dzienis, M.(2);Edwards, J.(1);
(1)Gold Coast University Hospital, Gastroenterology, Gold Coast, Australia;(2)Gold Coast University Hospital, Oncology, Gold Coast, Australia;
P539: COVID-19 is Associated with Long-term Elevated Fecal Calprotectin Levels in Patients with Crohn's Disease but not in Ulcerative Colitis.ECCO'22Year: 2022
Authors: Shafrir, A.(1,2);Benson, A.A.(1);Zinger, A.(1);Shauli Aharonov, M.(3);Katz, L.H.(1);
(1)Hadassah Medical Center, Department of Gastroenterology and Hepatology, Jerusalem, Israel;(2)Meuhedet Health Maintenace Organization, Jerusalem District, Tel Aviv, Israel;(3)Jerusalem College of Technology, Department of Industry and management, Jerusalem, Israel;
P540: Longitudinal Dynamics of Gut Microbiome and Metabolome After Biological Therapy in Inflammatory Bowel DiseasesECCO'22Year: 2022
Authors: Ahmed, M.(1);Metwaly, A.(1);Hammoudi, N.(2);Meng, C.(3);Köhler, N.(4);Le Bourhis, L.(2);Pauling, J.(4);Kleigrewe, K.(3);Allez, M.(2);Haller, D.(1);
(1)Technical University Munich, Chair of Nutrition and Immunology, Freising, Germany;(2)APHP- Hôpital Saint Louis- INSERM UMRS 1160- Paris Diderot- Sorbonne Paris-Cité University- Paris- France, Department of Gastroenterology, Paris, France;(3)Technical University of Munich, Bavarian Center for Biomolecular Mass Spectrometry BayBioMS, Freising, Germany;(4)Technical University of Munich, LipiTUM- Chair of Experimental Bioinformatics, Freising, Germany;
P542: Topical tacrolimus versus systemic biological therapy for refractory ulcerative proctitis: a retrospective cohort studyECCO'22Year: 2022
Authors: Crispino, F.(1);Michielan, A.(2);Tieppo, C.(2);Mazza, M.(2);Rogger, T.M.(2);Brinch, D.(1);Cappello, M.(1);Armelao, F.(2);
(1)University of Palermo, Gastroenterology & Hepatology Section- PROMISE, Palermo, Italy;(2)Santa Chiara Hospital, Gastroenterology and Digestive Endoscopy Unit, Trento, Italy;
P543: Point-of-care testing in therapeutic drug monitoring of infliximabECCO'22Year: 2022
Authors: Šahinović, I.(1);Orsic Fric, V.(2);Konjik, V.(3);Pavela, J.(4);Borzan, V.(5);Šerić, V.(1);
(1)University Hospital Osijek, Clinical department for laboratory diagnostics- University Hospital Osijek- Faculty of Medicine- J.J. Strossmayer University of Osijek, Osijek, Croatia;(2)University Hospital Osijek, Department of Gastroenterology- Clinic of Internal Medicine- University Hospital Osijek- Faculty of Medicine- J.J. Strossmayer University of Osijek, Osijek, Croatia;(3)University Hospital Osijek, Department of Pediatric Gastroenterology- Clinic of Pediatrics- University Hospital Osijek, Osijek, Croatia;(4)University Hospital Osijek, Clinical Department for Laboratory Diagnostics- University Hospital Osijek, Osijek, Croatia;(5)University Hospital Osijek, Department of Gastroenterology- Clinic of Internal Medicine- University Hospital Osijek, Osijek, Croatia;
P544: Patients with moderate to severe Crohn’s disease with and without prior biologic failure demonstrated improved clinical outcomes with risankizumab: Results from phase 3 induction and maintenance trialsECCO'22Year: 2022
Authors: D'Haens, G.(1);Beaton, M.(2);Bossuyt, P.(3);Dotan, I.(4);Sands, B.(5);Sugimoto, K.(6);Neimark, E.(7);Song, A.(8);Wallace, K.(8);Zhou, Q.(9);Kligys, K.(10);Ferrante, M.(11);
(1)Amsterdam University Medical Center, Department of Gastroenterology, Amsterdam, The Netherlands;(2)Western University, Department of Medicine- Division of Gastroenterology, London, Canada;(3)Imelda GI Clinical Research Centre, Department of Gastroenterology, Bonheiden, Belgium;(4)Rabin Medical Center, Division of Gastroenterology, Petah-Tikva, Israel;(5)Icahn School of Medicine at Mount Sinai, Dr. Henry D. Janowitz Division of Gastroenterology, New York, United States;(6)Hamamatsu University School of Medicine, First Department of Medicine, Hamamatsu, Japan;(7)AbbVie, Clinical Development, Worcester, United States;(8)AbbVie, Clinical Development, North Chicago, United States;(9)AbbVie, Statistics, North Chicago, United States;(10)AbbVie, Medical Affairs, Mettawa, United States;(11)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;
P545: Safety of ustekinumab in pregnant patients with inflammatory bowel disease and in their offspring: results from the DUMBO registry of GETECCUECCO'22Year: 2022
Authors: Chaparro, M.(1);Gutiérrez, A.(2);Calviño-Suárez, C.(3); Huguet, J.M.(4);Calvo, M.(5);Aguas, M.(6);Camargo Camero, R.(7);de Jorge Turrión, M.Á.(8);Hervías Cruz, D.(9);López Serrano, P.(10);Marín Pedrosa, S.(11);Martínez Montiel, P.(12);Rivero, M.(13);Vicente Lidón, R.(14);Arias García, L.(15);Arroyo, M.(16);Bujanda, L.(17); Casanova, M.J.(1);Figueiras, M.(18);Lucendo, A.J.(19);Manceñido Marcos, N.(20);Márquez, L.(21);Martín-Arranz, M.D.(22);Boscá Watts, M.(23);Ber, Y.(24);Ramírez de la Piscina Urraca, P.(25);Pérez-Martínez, I.(26);Robles, V.(27);Ruiz-Cerulla, A.(28);Vázquez Morón, J.M.(29);Madero, L.(2);Barreiro-de Acosta, M.(3);Capilla, M.(4);Vera Mendoza, I.(5);Acosta, D.(1);Brenes, Y.(1);Hermida, S.(1);Parra, P.(1);G. Donday, M.(1); Gisbert, J.P.(1);
(1)Hospital Universitario de La Princesa- Instituto de Investigación Sanitaria Princesa IIS-IP and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD, Gastroenterology Unit, Madrid, Spain;(2)Hospital General Universitario de Alicante- CIBERehd and Instituto de Investigación Sanitaria y Biomédica de Alicante ISABIAL, Gastroenterology Unit, Alicante, Spain;(3)Complexo Hospitalario Universitario de Santiago de Compostela, Gastroenterology Unit, Santiago de Compostela, Spain;(4)Hospital General Universitario de Valencia, Gastroenterology Unit, Valencia, Spain;(5)Hospital Universitario Puerta de Hierro Majadahonda, Gastroenterology Unit, Madrid, Spain;(6)Hospital Universitario y Politécnico La Fe and CIBEREHD, Gastroenterology Unit, Valencia, Spain;(7)Hospital Universitario Virgen de La Victoria, Gastroenterology Unit, Málaga, Spain;(8)Hospital Universitario de Cabueñes, Gastroenterology Unit, Gijón, Spain;(9)Hospital General Universitario de Cuidad Real, Gastroenterology Unit, Cuidad Real, Spain;(10)Hospital Universitario Fundación Alcorcón, Gastroenterology Unit, Madrid, Spain;(11)Hospital Universitario Reina Sofía, Gastroenterology Unit, Córdoba, Spain;(12)Hospital Universitario 12 de Octubre, Gastroenterology Unit, Madrid, Spain;(13)Hospital Universitario Marqués de Valdecilla e IDIVAL, Gastroenterology Unit, Santander, Spain;(14)Hospital Universitario Miguel Servet, Gastroenterology Unit, Zaragoza, Spain;(15)Hospital Universitario de Burgos, Gastroenterology Unit, Burgos, Spain;(16)Hospital Clínico Universitario Lozano Blesa and Fundación del Instituto de Investigación Sanitaria de Aragón IIS Aragón and CIBEREHD, Gastroenterology Unit, Zaragoza, Spain;(17)Instituto Biodonostia- Universidad del País Vasco UPV/EHU and CIBEREHD, Gastroenterology Unit, Guipúzcoa, Spain;(18)Hospital Álvaro Cunqueiro. Estrutura Organizativa de Xestión Integrada de Vigo, Gastroenterology Unit, Vigo, Spain;(19)Hospital General de Tomelloso. Instituto de Investigación Sanitaria Princesa IIS-IP and CIBEREHD, Gastroenterology Unit, Ciudad Real, Spain;(20)Hospital Universitario Infanta Sofía, Gastroenterology Unit, Madrid, Spain;(21)Hospital del Mar, Gastroenterology Unit, Barcelona, Spain;(22)Hospital Universitario La Paz e Instituto de Investigación Hospital Universitario La Paz IdiPAZ, Gastroenterology Unit, Madrid, Spain;(23)Hospital Universitario Clínico de Valencia, Gastroenterology Unit, Valencia, Spain;(24)Hospital Universitario San Jorge, Gastroenterology Unit, Huesca, Spain;(25)Hospital Universitario de Araba sede Txagorritxu y sede Santiago, Gastroenterology Unit, Álava, Spain;(26)Hospital Universitario Central de Asturias e Instituto de Investigación Sanitaria del Principado de Asturias ISPA, Gastroenterology Unit, Oviedo, Spain;(27)Hospital Universitario Vall d’Hebrón, Gastroenterology Unit, Barcelona, Spain;(28)Hospital Universitario de Bellvitge, Gastroenterology Unit, Barcelona, Spain;(29)Hospital Universitario Juan Ramón Jiménez, Gastroenterology Unit, Huelva, Spain;on behalf of DUMBO study group of GETECCU
P546: Minimal risk of lymphoma despite long term use of azathioprine in patients with Inflammatory Bowel Disease: a longitudinal cohort analysis from Northern India.ECCO'22Year: 2022
Authors: Ranjan, M.K.(1);Kante, B.(1);Vuyyuru, S.K.(1);Kumar, P.(1);Mundhra, S.K.(1);Golla, R.(1);Sharma, R.(2);Das, P.(3);Sahni, P.(4);Makharia, G.(1);Kedia, S.(1);Ahuja, V.(1);
(1)All India Institute of Medical Sciences, Department of Gastroenterology and Human Nutrition, New Delhi, India;(2)All India Institute of Medical Sciences, Department of Radio Diagnosis, New Delhi, India;(3)All India Institute of Medical Sciences, Department of Pathology, New Delhi, India;(4)All India Institute of Medical Sciences, Department of Gastrointestinal Surgery, New Delhi, India;
P547: Early modification of inflammatory burden through treatment with vedolizumab or adalimumab is predictive of long-term treatment success in patients with Ulcerative Colitis from the VARSITY StudyECCO'22Year: 2022
Authors: Schreiber , S.(1);Galinsky , K.(2);Aubrecht , J.(2);Juarez , J.(2);Agboton , C.(3);Loftus Jr , E.V.(4);Danese , S.(5);
(1)University Hospital Schleswig-Holstein, Department of Internal Medicine I, Kiel, Germany;(2)Takeda, Gastroenterology Drug Discovery Unit, Cambridge MA, United States;(3)Takeda Pharmaceuticals International, Global Medical Affairs, Zurich, Switzerland;(4)Mayo Clinic College of Medicine, Division of Gastroenterology and Hepatology, Rochester MN, United States;(5)IRCCS Ospedale and University Vita-Salute San Raffaele, Department of Gastroenterology, Milan, Italy;
